Literature DB >> 35348692

Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis.

Shiv Gandhi1, Sara Zelman1, Ricardo Eduardo De Armas2, Christopher Hemond3, Alexander N Levy1, Siddharth Singh4, Joshua Korzenik2, Sushrut Jangi1.   

Abstract

Entities:  

Keywords:  Anti-TNF therapy; Autoimmune disease; Demyelination

Mesh：

Substances：

Year:  2022        PMID： 35348692      PMCID： PMC9527605          DOI： 10.1093/ibd/izac053

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   7.290


× No keyword cloud information.
  8 in total

1.  The comeback kid: TYSABRI now FDA approved for Crohn disease.

Authors:  Karen Honey
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

2.  Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease.

Authors:  Hélène Zéphir; Corinne Gower-Rousseau; Julia Salleron; Olivier Simon; Marc Debouverie; Emmanuelle Le Page; Yoram Bouhnik; Christine Lebrun-Frenay; Caroline Papeix; Benoît Vigneron; Matthieu Allez; Lionel Prin; Jacques Cosnes; Patrick Vermersch; Jean-Frédéric Colombel
Journal:  Mult Scler       Date:  2013-12-10       Impact factor: 6.312

Review 3.  Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics.

Authors:  Siddharth Singh; Neeraj Kumar; Edward V Loftus; Sunanda V Kane
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

Review 4.  New IBD genetics: common pathways with other diseases.

Authors:  C W Lees; J C Barrett; M Parkes; J Satsangi
Journal:  Gut       Date:  2011-02-07       Impact factor: 23.059

5.  Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.

Authors:  Carlton W Thomas; Brian G Weinshenker; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2004-01       Impact factor: 5.325

6.  Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Authors:  Giancarlo Comi; Ludwig Kappos; Krzysztof W Selmaj; Amit Bar-Or; Douglas L Arnold; Lawrence Steinman; Hans-Peter Hartung; Xavier Montalban; Eva Kubala Havrdová; Bruce A C Cree; James K Sheffield; Neil Minton; Kartik Raghupathi; Ning Ding; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2019-09-03       Impact factor: 44.182

7.  Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.

Authors:  William J Sandborn; Brian G Feagan; Stephen Hanauer; Severine Vermeire; Subrata Ghosh; Wenzhong J Liu; AnnKatrin Petersen; Lorna Charles; Vivian Huang; Keith Usiskin; Douglas C Wolf; Geert D'Haens
Journal:  J Crohns Colitis       Date:  2021-07-05       Impact factor: 9.071

8.  Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.

Authors:  Stefan Schreiber; Jean-Frederic Colombel; Brian G Feagan; Kristian Reich; Atul A Deodhar; Iain B McInnes; Brian Porter; Ayan Das Gupta; Luminita Pricop; Todd Fox
Journal:  Ann Rheum Dis       Date:  2019-01-23       Impact factor: 19.103
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.